Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualized Hypoxia-guided Radiotherapy Combined With Standard Cisplatin-etoposide in Stage I-III SCLC

NCT01210131 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT01210131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01210131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualized Hypoxia-guided Radiotherapy Combined With Standard Cisplatin-etoposide in Stage I-III SCLC
Lead sponsor
Maastricht Radiation Oncology
Phase
Not applicable
Overall status
Withdrawn
Start date
July 31, 2013
Completion date
August 31, 2014
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer (sclc)